Khrom Capital pushes Acadia Healthcare to explore sale amid poor performance

Khrom Capital Management, holding a 5.5% stake in Acadia Healthcare (ACHC), has called for a formal strategic review, including a potential sale, citing the company's 71% share price underperformance over the past decade and governance issues. This activist push, mirroring Engine Capital's recent demand, highlights significant shareholder discontent amidst ACHC's mixed Q3 2025 preliminary results, ongoing federal investigations, and analyst downgrades, despite the stock trading at an undervalued 0.74 times book value.

Analysis

Acadia Healthcare (ACHC) is facing escalating pressure from activist investors, with Khrom Capital Management (5.5% stake) joining Engine Capital LP in demanding a formal strategic review, including a potential sale of the company. The activists' case is built upon severe, long-term share price underperformance, with the stock declining approximately 71% over both three- and ten-year periods, lagging both peers and market indices. Governance is a central point of contention, highlighted by long-tenured board members, a staggered board structure in place until 2029, and significant shareholder dissent, evidenced by 17.2 million votes against one director. This discontent is compounded by perceived strategic missteps, such as a failed UK expansion and an aggressive capital expenditure campaign. Financially, ACHC presents a mixed picture. While the company is trading at a low valuation of 0.74 times book value and has maintained profitability with a 5.64% trailing twelve-month revenue growth, it operates with a significant debt burden of $2.41 billion. Recent operational results have been weak, with preliminary Q3 2025 same-store patient day growth of 1.3% falling short of the 1.8% consensus, and Q2 results also missing expectations. External headwinds include an ongoing Department of Justice investigation and the threat of future Medicaid cuts, which prompted a BofA Securities downgrade to Neutral.

Key Decisions for Investors

• The intensified activist pressure from two separate firms materially increases the probability of a corporate event, such as a sale or significant restructuring, which could serve as a near-term catalyst to unlock shareholder value.
• Investors should weigh the stock's apparent undervaluation, trading at 0.74 times book value with sustained profitability, against considerable risks including a high debt-to-equity ratio, recent operational misses, and the uncertainty of an ongoing DOJ investigation.
• Monitor for the board's official response to the strategic review demands, as their willingness to engage could signal a shift in strategy and significantly impact the investment thesis.
• Consider the long-term headwind from potential Medicaid cuts expected in 2028, a key risk highlighted by BofA's downgrade that could pressure future earnings and valuation multiples.